ELElena A. Ljaljukova

Elena A. Ljaljukova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elena A. Ljaljukova has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Contribution of epicardial adipose tissue and fatty liver disease to the development of atrial fibrillation

    by D. V. Cherkashchenko, M. A. Livzan, E. A. Lyalyukova, Д. В. Черкащенко, М. А. Ливзан, Е. А. Лялюкова

    Obesity is a proven risk factor for cardiovascular diseases, including atrial fibrillation (AF). Adipose tissue is metabolically and hormonally active. In recent years, there has been a lot of discussion about whether ectopic adipose tissue, particularly excessive accumulation of fat in the epicardium and liver, can be a marker of cardiovascular diseases, particularly AF. Purpose of the publication - systematization and analysis of publications on the pro-inflammatory and hormonal role of ectopic adipose tissue (epicardial fat, liver) in the development of atrial fibrillation. Results. Epicardial fat, located in close proximity to the heart, is involved in structural remodeling and the progression of atrial fibrosis. Due to its close anatomical connection and shared blood supply with the heart, epicardial fat tissue directly affects its function. Pro-inflammatory cytokines and free fatty acids, when they enter the heart muscle, alter its electrical properties, contributing to atrial remodeling (fibrosis), a key mechanism in AF. The presence of non-alcoholic fatty liver disease (NAFLD) is associated with systemic inflammation and high levels of oxidative stress, which further worsens the metabolic condition of the myocardium. Moreover, the liver is a source of atherogenic lipid fractions, which exacerbates cardiovascular risk. Thus, epicardial fat and NAFLD represent an important intermediate link between metabolic disorders and AF. In order to prevent AF in patients with ectopic fat depots, it is necessary to identify and correct these risk factors in a timely manner.

  • Open Access

    Prevention of cholelithiasis: focus on the comorbid patient

    by E. A. Ljaljukova, Е. А. Лялюкова

    Background. The global prevalence of gallstone disease is remarkably high, affecting approximately 10-15% of the adult population in Western countries and 3-10% in Asian countries. This prevalence increases with age, reaching 30-50% in individuals over 70 years of age. Elderly patients and/or those with comorbidities often have contraindications to cholecystectomy; therefore, preventive measures and conservative therapy strategies are of particular relevance. Given the high prevalence of concominant conditions in patients with cholelithiasis, this therapy must be evaluated in terms of both efficacy and safety regarding all concomitant and underlying diseases. Results. Recent literature data indicate an increased risk of gallbladder and biliary tract diseases in comorbid patients. The risk of gallstones is highest in patients with metabolic disorders, such as type 2 diabetes mellitus, non-alcoholic fatty liver disease, obesity, insulin resistance, and lifestyle factors (dietary imbalances, low fiber intake, and physical inactivity). An increased risk of gallbladder disease may be associated with long-term glucagon-like peptide-1 receptor agonist use and bariatric interventions for obesity. Ursodeoxycholic acid constitutes the cornerstone of medical prophylaxis for cholelithiasis in this patient population. It exerts a potent choleretic effect and lowers the cholesterol content in bile, primarily by dispersing cholesterol and promoting the formation of a liquid-crystalline phase. Furthermore, this agent modulates the enterohepatic circulation of bile salts by inhibiting ileal reabsorption of more hydrophobic, potentially toxic endogenous compounds, thereby reducing the lithogenic index of bile by increasing its bile acid content. Beyond these biliary effects, the drug exhibits a direct hepatoprotective capacity, attenuating the hepatotoxicity of hydrophobic bile salts, and modulates immune responses by downregulating the aberrant expression of HLA antigens on hepatocytes and suppressing the production of cytokines and interleukins. Ultimately, these multi-targeted mechanisms improve the core metabolic syndrome components and help achieve a more pronounced effect in obesity management. Given that low dietary fiber intake increases the risk of cholelithiasis, dietary modification represents a crucial strategy for the prevention and treatment of gallstones.

  • Open Access

    Genes and protein-energy deficiency in patients with connective tissue dysplasia

    by Yu. S. Tsikunova, E. A. Lyalukova

    The article provides information on the role of the FTO (A+23525T) fat mass-associated gene polymorphism, the leptin receptor gene LEPR (Arg223Gln) in BEN syndrome in patients with DST. The results of the study of the trophological status of patients with DST and the severity of BEN syndrome are shown. It has been proven that genetic mutations exacerbate genetically determined disorders of the trophological status. In practice, the doctor must take into account the mechanisms of the formation of BEN syndrome in patients with DST and the risks associated with the presence of this syndrome.

  • Open Access

    Prevention of biliary diseases associated with GLP-1 receptor agonist therapy

    by E.A. Ljaljukova

    Background. In recent years, glucagon-like peptide-1 receptor agonists (GLP-1a) have emerged as pivotal therapeutic agents in the management of metabolic disorders, particularly type 2 diabetes mellitus and obesity. This is due to their ability to improve glycemic control and facilitate weight loss by enhancing insulin secretion, suppressing glucagon release and delaying gastric emptying by promoting prolonged satiety and reducing appetite. However, despite their clinical efficacy, therapy with GLP-1RAs has been associated with an increased risk of gallbladder disease, especially with prolonged use and higher doses. Objective. The aim of this study is to evaluate current clinical data regarding the incidence and severity of adverse effects involving gallbladder and biliary tract in patients receiving GLP-1αtherapy, to evaluate potential prevention strategies and to assess the efficacy of ursodeoxycholic acid (UDCA) in this patient population. The objective of this review is to examine the potential mechanisms through which GLP-1 receptor agonists may contribute to the development of biliary tract diseases. Recent systematic reviews, meta-analyses and Randomized Controlled Trials (RCTs) indicate an increased risk of gallbladder and biliary tract diseases with GLP-1 receptor agonist therapy. The risk is highest with high-dose and long-term therapy, as well as in patients treated for weight loss and type 2 diabetes mellitus (T2DM). The increased risk of gallbladder diseases associated with GLP-1 receptor agonists therapy has important clinical implications necessitating careful monitoring of the gallbladder and biliary tract before initiation, as well as of patients receiving GLP-1 receptor agonist therapy. UDCA positively affects choleresis, reduces the inflammation and improves metabolic parameters; therefore, it is recommended for the prevention and treatment of adverse events associated with GLP-1 receptor agonist therapy.


  • Open Access

    Multicomponent biocomplex consisting of Bifidobacterium lactis HN019TM, Lactobacillus acidophilus NCFM® 109 and 1010, alphaand beta-galactosidase, extracts of lemon balm, chamomile, passionflower, and ginger for the treatment of lactase deficiency and irritable bowel syndrome

    by L. B. Lazebnik, E. A. Lyalukova

    One of the diseases that occurs under the “mask” of irritable bowel syndrome (IBS) is disaccharidase deficiency, which develops due to the deficiency of disaccharide hydrolysis enzymes. The probability of disaccharidase deficiency in a patient with IBS-like symptoms is quite high and reaches 22-26%. Disaccharide intolerance develops against the background of congenital or acquired galactosidase deficiency. Beta-galactosidase is an enzyme, often called lactase, that catalyzes the reaction of hydrolytic cleavage of non-reducing residues of beta-D-galactose in milk sugar, the disaccharide lactose. Impaired or decreased synthesis of beta-galactosidase is the cause of intolerance to milk and dairy products. Lactose intolerance is diagnosed based on a thorough collection of complaints, anamnesis, physical examination and medical tests. A connection between symptoms and the intake of dairy products is traced. In this regard, a patient who has come to the doctor for the first time with IBS symptoms is recommended to keep a food diary. Poor milk tolerance appears within 1-1.5 hours after consuming dairy products. Rumbling, abdominal pain, loose stools and bloating appear. The severity of clinical manifestations of lactase deficiency often does not correlate with the degree of decrease in enzyme activity. Lactose intolerance is associated not only with the level and activity of the enzyme, but also with the number of lactose-fermenting bacteria. Lactase deficiency is combined with manifestations of excessive bacterial growth in the small intestine, which affects the clinical symptoms and their duration. Diagnosis is made by performing a hydrogen breath test to confirm excessive colonization of the small intestine. Treatment of lactose intolerance involves dietary changes, taking lactase-containing enzymes, and treating the underlying disease in patients with secondary lactase deficiency.


  • The role of gut microbiota, short-chain fatty acids, and bile acids in the development of gallstone disease

    by E.A. Ljaljukova, T.N. Makarov, A.V. Lyalyukov, N.S. Cheuzheva

    Background. Gallstone disease remains one of the most common pathologies of the hepatobiliary system. Objective. The purpose of this review is to systematize current data on the pathogenesis of gallstone disease, the role of bile acids and short-chain fatty acids, and gut microbiota in the development of systemic inflammation leading to the formation of cholesterol gallstones. Results. The pathogenesis of cholesterol gallstone formation involves several factors, the most significant of which include genetic predisposition, imbalance between bile components (such as cholesterol, bile acids, and phospholipids), motility disorders of the biliary tract, and systemic inflammation. Bile acids play a key role in stabilizing the physicochemical and colloidal properties of bile. Disruptions in gut microbiota lead to insufficient production of hydrophilic ursodeoxycholic acid and increased absorption of toxic primary bile acids. In contrast, ursodeoxycholic acid exhibits a wide range of pleiotropic effects, including modulation of the bile acid pool, acting as a cytoprotective, immunomodulatory, and choleretic agent. The gallbladder microbiota closely interacts with the gut microbiota. Short-chain fatty acids, produced by gut microbiota, inhibit pathogenic bacteria, stimulate the immune system to mount a specific response, and mitigate inflammatory reactions. They serve as universal "signaling" molecules involved in intra- and intercellular communication. One mechanism involves interaction with nuclear acetyl-CoA, regulating the expression of genes responsible for pro-inflammatory cytokine production. Due to their small size, short-chain fatty acids passively diffuse through cell membranes or are actively transported via sodium-coupled transporters, entering the cytoplasm and even the nucleus of eukaryotic cells. There, they inhibit histone deacetylase activity, regulating acetylation and thus epigenetically dependent gene expression related to cell proliferation, differentiation, epithelial integrity, and immune response. Conclusion. Short-chain fatty acids and bile acids are key molecules in regulating the "gut-liver-gallbladder" axis, which may be crucial for developing new therapeutic approaches for biliary tract diseases.

  • Osteoporosis in patients with non-alcoholic fatty liver disease: a review of the literature

    by E.A. Ljaljukova, E.N. Chernysheva, A.V. Lyalyukov

    Background. Nonalcoholic fatty liver disease and osteoporosis are two common metabolic diseases. The prevalence of non-alcoholic fatty liver disease in populations is as high as 38%, with a much higher prevalence among obese and/or type 2 diabetics. The global prevalence of osteoporosis is estimated at 19.7%, varying considerably between countries and continents, and statistics show that the region and the level of solar activity do not determine the prevalence of the problem. Like non-alcoholic fatty liver disease, osteoporosis is latent for a long time, without a manifest clinical picture. It is quite logical to ask whether non-alcoholic fatty liver disease is an important component of the pathogenesis of osteoporosis or whether these are two frequently occurring diseases. Objective. The objective of this literature review was to summarise the experimental and clinical evidence on the potential association between non-alcoholic fatty liver disease and osteoporosis. Results. Non-alcoholic fatty liver disease as a manifestation of metabolic syndrome based on insulin resistance affects bone metabolism, increasing the risk of osteoporosis and its complications. Current literature suggests that non-alcoholic fatty liver disease affects bone metabolism in several ways: through alterations in systemic and local bone marrow immune status, modulating insulin-like growth factor-1 levels, gut microbiota composition, short-chain fatty acid metabolism and intestinal barrier integrity. Some studies have shown that bile acids produced by the liver have a protective effect on bone tissue. Bile acids are able to reprogram pro-inflammatory macrophages into their anti-inflammatory phenotypes, thereby reducing the degree of systemic inflammation. Normalising the interplay between the microbiome, immunity and bone metabolism may open new avenues for the treatment of osteoporosis in the future.

  • Improving the effectiveness of eradication therapy for Helicobacter pylori infection

    by E.A. Ljaljukova, E.N. Chernysheva

    Background. Butyric acid (butyrate) is a short-chain fatty acid produced by anaerobic bacteria of the species Eubacterium rectale, Eubacterium ramulus, Eubacterium hallii, Roseburia cecicola, Roseburia faecis, Faecalibacterium prausnitzii and Coprococcus faecalis, as well as Fusobacteria, non-pathogenic Clostridium species, plays a key role in the physiology of the gastrointestinal epithelium. The protective effect of butyrate is realised on the part of gastric and intestinal mucosa by stimulation of anti-inflammatory and antioxidant mechanisms. Being a source of energy, it affects a wide range of cellular functions, exerting cytoprotective effect and maintaining homeostasis within the gastrointestinal tract. Butyric acid maintains the integrity of the mucosal barrier, stimulating the production of protective mucus and antimicrobial proteins, and increases the density of epithelial contacts with each other, as well as has an anti-inflammatory effect. Due to pH regulation (creates a slightly acidic environment) promotes the creation of favourable conditions for the growth of its own beneficial microbiota and unfavourable for opportunistic and pathogenic microbiota. In addition to pleiotropic effects on the human macroorganism, butyric acid and its derivatives have a direct antibacterial effect. Uric acid is able to inhibit the growth of Helicobacter pylori and have a destructive effect on the cell membrane of the microorganism, reducing cytoplasmic pH and accumulating toxic anions to prevent colonisation of Helicobacter pylori, generating hydrogen peroxide and damaging pathogenic proteins, membrane lipids and DNA of the bacterial cell. Conclusion. In Russia, as a source of butyric acid (butyrate), a preparation has been registered which, in addition to butyric acid, contains a second active component – inulin, a soluble dietary fibre, which creates a nutritious environment for the intestinal microbiota, thus stimulating the growth of beneficial bacteria and having a prebiotic effect.

  • Open Access

    Eating behavior in patients with metabolically associated fatty liver disease

    by A. A. Khalashte, E. A. Lyalyukova, S. K. Zhachemuk, Z. A. Beslangurova, G. N. Zhernakova

    The purpose of this study was to study the phenotypes of eating behavior in patients with NAFLD and their determining factors. Discussion: fatty liver disease has a high prevalence (24-26%) with an upward trend in both developed and developing countries, and in the coming years may become one of the main causes of liver transplantation. The clinical features of the disease are in most cases its asymptomatic course, which can progress to fibrosis/cirrhosis and is associated with the risk of a number of serious extrahepatic diseases (cardiovascular, oncological and others). The mechanisms underlying the formation of increased health risks and disease prognosis are multifactorial. Metabolic disorders, orthorexia nervosa, eating disorders and vegetative effects are considered as possible pathogenetic mechanisms for increasing the risk of NAFLD incidence. Conclusion: the study showed that complex behavioral psycho-social factors are involved in the pathogenesis of NAFLD, and changing eating behavior is an important component of therapy. Dysfunctional eating behavior can be a barrier to long-term success from therapy.


  • Open Access

    Fatty liver disease: heterogeneous phenotype

    by A. A. Khalashte, E. A. Lyalyukova, S. K. Zhachemuk, Ya. A. Goncharov, S. I. Rakhmanova, G. N. Zhernakova

    Relevance. Nonalcoholic fatty liver disease (NAFLD) holds a leading position among the causes of diffuse liver diseases, both in Russia and globally. Moreover, there is a persistent trend of increasing prevalence, especially among patients with metabolic risk factors. The Purpose of the Study: To assess the frequency of detecting fatty liver disease associated with metabolic syndromes in the Republic of Adygea and elucidate the characteristics of disease phenotypes across different age groups. Materials and methods. At stage I, 412 patients aged 18-89 years (45.4% male, 54.6% female) who visited outpatient clinics of therapeutic profile were examined. The average age of the patients was 57.0 ± 15.1 years. At stage II, the study was continued with patients diagnosed with NAFLD. Inclusion criteria for the study were: age 18 years and older, presence of fatty liver disease associated with metabolic conditions. The study continued with 191 patients diagnosed with metabolic associated fatty liver disease (MAFLD) (42.4% male, 57.6% female). The average age of the patients was 60.0 ± 12.4 years. Exclusion criteria from the study were: acute inflammatory diseases or exacerbation of chronic diseases during the study period, presence of viral hepatitis, alcoholic liver disease, autoimmune liver diseases, pregnancy, lactation, and use of medications or narcotics. The diagnosis of fatty liver disease was established in accordance with the recommendations of the Scientific Society of Gastroenterologists of Russia (2021) and the Russian Gastroenterological Association (2022). The diagnosis of metabolic-associated fatty liver disease (MAFLD) was based on visual evidence of hepatic fat accumulation (steatosis) obtained through ultrasonography, accompanied by one of the following criteria: excess body weight or obesity, type 2 diabetes mellitus, and/or signs of metabolic changes, defined as the presence of at least two of the following criteria: MS1 - waist circumference (WC) ≥102 cm in men and ≥88 cm in women; MS2 - body mass index (BMI) ≥25 kg/m²; MS3 - prediabetes (impaired fasting glycemia), homeostatic model assessment of insulin resistance (HOMA-IR) index ≥2.5; MS4 - presence of type 2 diabetes mellitus (T2DM); MS5 - blood pressure ≥130/85 mmHg or the patient receiving specific pharmacological treatment; MS6 (serum C-reactive protein >2 mg/L); MS7 - presence of dyslipidemia or the patient receiving specific pharmacological treatment. Patients were divided into age groups as follows: 18-44 years - young age (Group I); 45-59 years - middle age (Group II); 60-74 years - elderly age (Group III); 75-89 years - old age (Group IV). The study was approved by the Ethics Committee of the Federal State Budgetary Educational Institution “Maykop State Technological University, Medical Institute”. Results. The frequency of detection of fatty liver disease associated with metabolic syndromes in the Republic of Adygea, according to population screening data, was 46.4% (n=191). Out of 191 patients with ultrasound-detected evidence of steatosis, one in every fourth patient (25.1%, n=48) had deviations in liver test parameters from the reference values (laboratory signs of steatohepatitis). There were an average of 4.6±1.0 syndromes per patient in the age group 18-44 years. In the age group of 45-59 years, the average was 4.7 ± 1.1 syndromes, in the age group of 60-74 years, it was 5.0 ± 0.9, and in the age group of 75-89 years, it was 4.8 ± 1.0 syndromes, without statistical differences between the groups. In the age group of 18-44 years, the highest proportion was represented by lipid metabolism disorders (77.8%) and impaired glucose tolerance, HOMA-IR >2.5 (38.9%). In the age groups of 45-59 years and 60-74 years, the highest proportion was represented by type 2 diabetes mellitus (80.3% and 98.9%, respectively) and arterial hypertension (83.6% and 91.6%, respectively). In the age group of 75-89 years, the highest proportion was represented by type 2 diabetes mellitus (100%), elevated levels of serum C-reactive protein (58.8%) (indicating systemic inflammation), and chronic kidney disease (100%). The identified associations suggest the presence of specific age-related disease phenotypes, necessitating an appropriate volume of preventive measures and targeted therapy.